ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / CPIX / earnings
GOSS (33) SPRO (43) FBIO (39) RNXT (31) ⌘ Pro Terminal →

Cumberland Pharmaceuticals Inc. (CPIX) Next Earnings Date & Expected ±12.5% Move

$4.69 +7.82% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.75

Cumberland Pharmaceuticals Inc. (CPIX) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE D- • RED ALERT Cap $65.2M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CPIX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CPIX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $4.69 (+7.82% 1D, market cap $65.2M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 11/20. Across 1016 tracked Health Care issuers, CPIX ranks #590 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CPIX compare to GOSS and SPRO in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CPIX carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of 85.0%, and ROIC of -16.4%. By comparison, GOSS (Gossamer Bio Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $65.4M) and SPRO (Spero Therapeutics Inc.) posts a D- grade (43/100 RQD, P/E 7.5x, ROIC 26.6%, cap $64.6M). Among the 5-stock peer group, SPRO leads on earnings multiple (7.5x) while SPRO leads on capital efficiency (26.6% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CPIX?
▼

Per CPIX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001087294), Cumberland Pharmaceuticals Inc. generated $44.5M in revenue (+17.6% YoY), -$2.8M in net income, and $4.8M in free cash flow against $76.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $4.75 (+1.22%)🧬 Cannibal Buyback (-0.96% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 10.9% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.8% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510038
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D-
Cash (6)Whales (4)SEC (7)Macro (10)CEO (11)
Each axis scored 0–20
12M PRICE TARGET CONE-9% Base Target
$10 Bull$4 Base$3 Bear
📬 FREE CPIX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CPIX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (38/100 Composite)
🔍 WHY CPIX SCORES 38/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Insider Conviction & Share Dilution+11/20 pts (29% of score)

SEC Form 4 / 13F Thermometer: 55% Net Buy • Cannibal Buyback (-0.96% YoY Shares)

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (26% of score)

FRED Regime × Technicals: 38% of 52W Range • RSI-14 at 35.3 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
46
Grade D$7.03+2.1% Next Q
Q2 (-2Q)
43
Grade D$7.18+18.2% Next Q
Q3 (-1Q)
41
Grade D$8.49-44.8% Next Q
Current
38
Grade D-$4.69-7.8% Hist 90D α
Trajectory: D (46) → D- (38)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CPIX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CPIX currently carries a cautious 38/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($7.12) and Max Pain ($4.92) forces dealer call-delta covering toward $9.74.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Cannibal Buyback (-0.96% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CPIX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CPIX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 38%NO 62%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 30, 2026 (~57 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.59 Expected Swing
$4.10 (-12.5%)Spot $4.69$5.28 (+12.5%)
MODEL EARNINGS SETUP GAUGE

CPIX Quantitative Pre-Earnings Setup: 38/100

Trailing EPS: $4.25 • YoY Revenue Growth: 17.6%

Model Bullish Setup (38/100)Model Risk Weight (62/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$44.5M-$2.8M$4.8M85%
FY 20242024-12-31$37.9M-$6.5M-$678.6K82.6%
FY 20232023-12-31$39.6M-$6.3M$6.1M85%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CPIX)

  • ✓Walkthrough of CPIX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
CPIX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +11.93%▼ DESCENDING CHANNEL
2026-10-30O $4.35H $4.76L $4.35C $4.69VOL 129.0K
RES: $8.70SUP: $4.16SMA50: $7.12SMA200: $5.52
$9.69$7.98$6.27$4.56$2.85RES $8.70SUP $4.16$4.692026-04-302026-06-152026-07-312026-09-162026-10-30
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CPIX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CPIX Butterfly Map → + Track CPIX →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +17.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CPIX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CPIX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CPIX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CPIX)

Health Care Rank #590 of 1016 ⚔️ GOSS vs CPIX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CPIX vs. GOSS, SPRO, FBIO, RNXT)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Cumberland Pharmaceuticals Inc. (CPIX) ranks #590 by composite RQD confidence (38/100, grade D-) and #718 by equity capitalization ($65.2M). Within this direct 5-issuer industry benchmark cohort, SPRO leads on earnings valuation at 7.5x trailing P/E, while SPRO leads on capital efficiency and profitability with 26.6% ROIC and — gross margin. SPRO currently holds the highest overall quantitative score in the immediate peer group at 43/100 (D-) compared with CPIX at 38/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
CPIX ACTIVE
Cumberland Pharmaceuticals Inc.
D- 38/100 — 85.0% -16.4% +7.82% $65.2M Benchmark Subject
GOSS
Gossamer Bio Inc.
E 33/100 — — -35.0% -2.90% $65.4M /goss-vs-cpix →
SPRO
Spero Therapeutics Inc.
D- 43/100 7.5x — 26.6% -4.50% $64.6M /spro-vs-cpix →
FBIO
Fortress Biotech Inc.
D- 39/100 — 66.9% -35.0% -4.00% $66.7M /fbio-vs-cpix →
RNXT
RenovoRx Inc.
E 31/100 — 70.9% -35.0% -10.74% $67.2M /rnxt-vs-cpix →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001087294

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cumberland Pharmaceuticals Inc. (CPIX) reported GAAP revenue of $44.5M (+17.6% vs. FY2024 revenue of $37.9M , and +12.6% cumulative change since FY2023) , GAAP net income of -$2.8M, operating cash flow of $4.9M, and free cash flow of $4.8M (+812.4% YoY). On the balance sheet, CPIX closed FY2025 with $76.8M in total assets against $0 in total debt (Altman Z-Score: 0.72, Piotroski F-Score: 7/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $44.5M -$2.8M $4.9M $4.8M $76.8M —
FY2024 (FY) 2024-12-31 $37.9M -$6.5M -$612.2K -$678.6K $75.6M —
FY2023 (FY) 2023-12-31 $39.6M -$6.3M $6.1M $6.1M — —

3. CPIX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CPIX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $4.69 (+7.82% 1D, market cap $65.2M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 11/20. Across 1016 tracked Health Care issuers, CPIX ranks #590 in composite RQD confidence.

How does CPIX compare to GOSS and SPRO in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CPIX carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of 85.0%, and ROIC of -16.4%. By comparison, GOSS (Gossamer Bio Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $65.4M) and SPRO (Spero Therapeutics Inc.) posts a D- grade (43/100 RQD, P/E 7.5x, ROIC 26.6%, cap $64.6M). Among the 5-stock peer group, SPRO leads on earnings multiple (7.5x) while SPRO leads on capital efficiency (26.6% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CPIX?

Per CPIX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001087294), Cumberland Pharmaceuticals Inc. generated $44.5M in revenue (+17.6% YoY), -$2.8M in net income, and $4.8M in free cash flow against $76.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CPIX trading relative to its 50-day, 200-day, and 52-week technical levels?

CPIX last traded at $4.69 (+7.82% on volume of 128,962 shares), positioning the stock -34.13% below its 50-day simple moving average ($7.12) and -15.04% below its 200-day simple moving average ($5.52). Across its 52-week range of $1.85 to $9.28, CPIX sits at the 38.2% percentile with a 14-day RSI of 35.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($4.10 to $5.28).

CPIX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is CPIX's next earnings date?

Based on SEC filing cadence, Cumberland Pharmaceuticals Inc. (CPIX)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is CPIX stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for CPIX, spanning a range between $4.1 and $5.28.

Direct Sub-Reports: CPIX RQD Cockpit CPIX 12M Forecast CPIX Earnings & Move CPIX Dividends & DRIP CPIX Insiders & 13F CPIX Whale Options CPIX Profit Sankey CPIX News & Why
ROARABLE RATING BRIEF • RQD 38/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

CPIX — Cumberland Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Engine: Haiku 5.5 Dossier Pipeline
As of: 2026-11-02T14:24Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD 5-pillar rating engine, Cumberland Pharmaceuticals Inc. (CPIX) carries a composite score of 38/100 (D- — Roarable Sell — Vulnerable Balance Sheet & Flow) at a current price of $4.69 (+7.82%). Fundamental cash generation scores 6/20 (ROIC -16.4%, FCF yield 7.42%), institutional 13F whale accumulation scores 4/20, insider conviction scores 11/20, macro regime alignment scores 10/20 (Beta 1.00), and forensic balance-sheet protection scores 7/20 (Altman Z-Score 0.72, Piotroski F-Score 7/9).

Investor Implication: At current trailing P/E and current forward P/E within Biotechnology: Pharmaceutical Preparations, upside depends on sustained operating margin expansion (-6.3%) and free cash flow conversion relative to the 52-week range of $1.85 – $9.28.

Butterfly Effect: Supply-Chain, Sector & Catalyst Ripples

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), CPIX is sensitive to 2nd-order capital expenditure cycles, input cost spreads (gross margin 85.0%), and institutional positioning across its peer cohort. Prospective investors should monitor quarterly order backlog conversion, sector capex guidance, and Form 4 insider cluster activity (0 recent filings tracked).

Open Questions to Watch: (1) Margin trajectory vs. peer median; (2) FCF conversion sustainability over the next 4 quarters; (3) Institutional 13F rebalancing around upcoming earnings.

CPIX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Cumberland Pharmaceuticals Inc. (CPIX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CPIX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CPIX Bull vs. Bear Conversation Board — What's Your Call at $4.69?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CPIX 🐻 67% BEARISH CONVICTION
1. Pick Your Side on CPIX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $4.13 (-11.9%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is CPIX (D- • RQD 38/100) a Buy at $4.69?

Welcome to the CPIX (Cumberland Pharmaceuticals Inc.) Roar Pit. Current RQD Composite is 38/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SK SkepticalCFA Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $3.75 (-20.0%)
Spot @ $4.69

Pump the brakes on CPIX — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on CPIX, but look at what you are paying: current EV/EBITDA multiples with 85.0% gross margins. Unless Cumberland Pharmaceuticals Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH 🎯 Target: $5.53 (+17.9%)
Spot @ $4.69

CPIX cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on CPIX, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $4.69 (52-wk range $1.85 - $9.28), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%